Uracil/tegafur plus oral calcium folinate in advanced breast cancer

Richardet, Eduardo Arnoldo, Pedraza, Cecilia, Mickiewicz, Elizabeth, Lerzo, Guillermo, Bonamasa, Miguel, Coppola, Federico, Elli, Alicia, Uranga, Graciela, Jovtis, Silvia, Bruno, Mario, Ventriglia, Mónica and Cuevas, María Andrea (1999) Uracil/tegafur plus oral calcium folinate in advanced breast cancer. Oncology, 13 (7). pp. 96-97. ISSN 0890-9091

PDF - Versión aceptada Disponible bajo Licencia CC Atribución-NoComercial-SinDerivadas 4.0 Internacional. Descargar (61kB)

Resumen

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase H trial investigating the feasibility of 250 mg/m2/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation.

Tipo de documento:	Artículo
Palabras clave:	Aminoglutethimide. Anthracycline. Antineoplastic agent. Cyclophosphamide. Fluorouracil. Folinate calcium. Methotrexate. Mitomycin C. Mitoxantrone. Navelbine. Orzel. Paclitaxel. Tamoxifen. Tamoxifen citrat. UFT. Unclassified drug. Uracil.
Temas:	R Medicina > R Medicina (General)
Unidad académica:	Universidad Católica de Córdoba > Facultad de Ciencias de la Salud
Google Académico:	Ver citaciones
URI:	http://pa.bibdigital.ucc.edu.ar/id/eprint/3734

Editar ítem